普洛藥業(000739.SZ)2020年度淨利潤升47.58%至8.17億元 擬10派2.43元
格隆匯 3 月 11日丨普洛藥業(000739.SZ)發佈2020年年度報吿，實現營業收入78.80億元，同比增長9.28%；歸屬於上市公司股東的淨利潤8.17億元，同比增長47.58%；歸屬於上市公司股東的扣除非經常性損益的淨利潤6.91億元，同比增長30.48%；基本每股收益0.6930元，擬每10股派發現金紅利2.43元(含税)。經營活動產生的現金流量淨額10.60億元，同比下降22.10%。
經過近二十年的深耕細作與積累，公司CDMO業務具有“化學合成+生物發酵”雙輪驅動的技術能力和“多客户、多產品”的競爭優勢，主要工廠都獲得WHO、美國FDA、歐盟COS、德國GMP、日本PMDA等國際組織認證，現已成為多家國際大型藥企的戰略供應商。公司持續加大CDMO的投入力度，研發能力和製造能力已躋身國內同行前列，並能為國內外大型創新藥企提供高效、全面、優質的一站式定製研發和生產服務。隨着公司CDMO研發能力的不斷提升，承接的新項目數量也明顯增加。報吿期內，公司新報價CDMO項目有540個；正在進行的CDMO項目有200個，其中研發服務項目88個，商業化人用藥項目74個，商業化獸藥項目25個，其他商業化項目13個。本年度項目數較去年同期增長40%左右，其中臨牀前及I期、II期項目增加較為明顯。另外，公司在保持國外CDMO業務正常發展的同時，國內CDMO業務也展現了突飛猛進的良好勢頭。截止報吿期末，公司已與國內70餘家創新藥客户簽訂了保密協議，並已與部分客户開展了業務合作。
報吿期，公司CDMO業務強勁增長，實現營業收入10.55億元，較上年同期增長46.14%；實現毛利率41.62%，較上年同期增加4.33個百分點。
隨着CDMO研發人員的不斷擴充、上海CDMO新實驗樓的投入使用以及流體化學實驗室、高活性物質(API)實驗室、兩個高活性藥物車間、兩個多功能CDMO標準化車間和四個原料藥生產車間的陸續建成並投入運行，將進一步提升公司CDMO的研發能力和生產能力，最大限度地滿足國內外客户的需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
